Nutex Health Inc. (NUTX) Form 8-K — Nov 5, 2026
Nutex Health reported Q3 2026 revenue of $217.6 million, down 18.7% year over year, with net income attributable to Nutex of $40.2 million ($5.71 diluted EPS) versus $55.4 million ($7.76) a year ago. The nine-month picture is stronger: net income rose 159% to $152.9 million ($21.50 diluted EPS), aided by a $52.3 million non-cash contract services reduction tied to the June 2026 HaloMD agreement amendment and lower CMS administrative fees, which added $25.0 million or $4.83 per diluted share.
Key figures
- Eps
- 5.71
- Revenue
- 217613000
- Net Income
- 40229000
- Total Debt
- 34200000
- Revenue Yoy
- -18.7% (Q3 2026 vs Q3 2025)
- Total Assets
- 1032376000
- Cash Position
- 249911000
- Q3 ebitda
- 63345000
- Q3 visits yoy
- +18.1%
- Q3 total visits
- 54622
- Nine month revenue
- 644850000
- Q3 2025 net income
- 55435000
- Q3 adjusted ebitda
- 63877000
- Shares outstanding
- 6857504
- Q3 2025 diluted eps
- 7.76
- Nine month net income
- 152878000
- Nine month diluted eps
- 21.5
- Nine month revenue yoy
- -10.9%
- Nine month operating cash flow
- 188065000
- Halomd change in estimate benefit
- 52319000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.